NeoGenomics stock falls 2.81 percent after Q2 revenue beat

NeoGenomics stock fell 2.81 percent to USD 18.36 on Nasdaq on September 23, 2026, leaving the shares 8.43 percent below their 52-week high of USD 20.05. The move came as investors weighed the company's latest oncology strategy against a second-quarter revenue beat.

Q2 revenue rises 11.2 percent

NeoGenomics reported second-quarter 2026 revenue of USD 201.66 million, up 11.2 percent from the same period a year earlier, according to MarketBeat. The figure exceeded the reported consensus estimate of USD 196.93 million, while adjusted EPS reached USD 0.05 against expectations of USD 0.03.

The result gives the stock a clear operating counterpoint to its recent volatility. Revenue growth is visible in the reported numbers, but the market still values the company on whether higher testing volumes can translate into durable profitability.

Precision oncology takes center stage

At the Morgan Stanley 24th Annual Global Healthcare Conference, held September 14 through September 16, 2026, NeoGenomics executives highlighted next-generation sequencing, minimal residual disease testing and workflow tools for community oncologists, as reported by Yahoo Finance. The strategy connects laboratory testing with treatment monitoring and expands the company's role beyond conventional pathology services.

NeoGenomics also announced its participation in the conference on September 1, 2026, describing the business as an oncology diagnostics provider serving oncologists, pathologists, hospitals and pharmaceutical companies, according to the company's investor release. That mix leaves clinical revenue as the central operating indicator for the next update.

Stock remains below yearly peak

NeoGenomics stock stood at USD 18.36 on September 23, 2026, with a 52-week range of USD 7.07 to USD 20.05. The price was USD 0.53 below the prior close of USD 18.89, a daily comparison that puts the latest decline in perspective while keeping the shares well above the yearly low.

The next scheduled earnings date is October 27, 2026, before market open, according to Stock Analysis. Until then, the key measurable test is whether the 11.2 percent revenue increase can support improving earnings quality.